← Back to Search

RIMO for Opioid Use Disorder (RIMO Trial)

N/A

Waitlist Available

Led By Christine E Grella, Ph.D.

Research Sponsored by Chestnut Health Systems

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Experienced an opioid overdose reversed with naloxone administered by first responders on a participating team within the past week

Be older than 18 years old

Must not have

Cognitively unable to provide informed consent

Under age 18

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 9 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new intervention for people who have overdosed on opioids and been given naloxone by first responders, but have not entered into MAT. The intervention is called Recovery Initiation and Management after Overdose (RIMO), and it is designed to help people connect to treatment and recovery support.

Who is the study for?

This trial is for adults in Chicago who've had an opioid overdose reversed with naloxone by first responders in the past week, are not currently in treatment, and have a positive screen for Opioid Use Disorder. They must be over 18, able to consent, and speak English.

What is being tested?

The study compares two approaches: usual referral to Medication-Assisted Treatment (MAT) versus Recovery Initiation and Management after Overdose (RIMO), which includes assertive linkage to MAT and ongoing recovery support.

What are the potential side effects?

Since this trial focuses on referral methods rather than medications, there aren't direct side effects from interventions like drugs. However, participants may experience stress or anxiety during recovery initiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was revived from an opioid overdose with naloxone by first responders within the last week.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am unable to understand and give consent for treatment.

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 9 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~9 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Length of Staying on Medication

MAT Days

MAT Time to Initiation

Secondary study objectives

Cost of Health Care Utilization

Mental Health: Externalizing Symptoms

Mental Health: Internalizing Symptoms

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Recovery Initiation and Management after Overdose (RIMO)Experimental Treatment2 Interventions

Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.

Group II: Passive Referral ControlActive Control1 Intervention

Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.

0 / 3Eligibility criteria met